Financial Performance and Subsidiaries Revenue
RESILIENT DOMESTIC PHARMA BUSINESS
OVERVIEW OF DOMESTIC PHARMA BUSINESS
Three key business segments: Oncology, Pharma specialty and Cardiology & Diabetology
Focus on niche molecules with high barriers to entry. Majority of launches in India are first-time branded generics
Strategic entry into high volume mass market with innovative products
Promising pipeline of ~40 innovative molecules for future growth in specialty business
Launched 11 products across the three business segments during FY 2022-23
DOMESTIC FORMULATION SALES(¹) (₹ IN MILLION)
ONCOLOGY
NATCO
One of the leaders in the branded oncology medicines in India
Two decades of strong presence in oncology segment with 54(¹) in
2022-23
Portfolio of well recognized brands - 6 brands with INR 100mn+ sales
in the oncology segment
Widened its oncology product range with introduction of additional
therapy options for liver/kidney/prostrate cancers and entering into
the untapped market of ovarian cancer with a novel agent
PHARMA SPECIALTY
7,347
7,202
5,405
4,770
4,101
3,749
FY 2018
FY 2019
FY 2020
FY 2021
FY 2022
FY 2023
FY numbers have been prepared under Ind AS
(1) Represents gross revenue
23 Brands in #1 position in
indicated prescription
Around 650 sales force in
India
8 Brands in excess of INR
100mn+ sales
6,000+ doctors engaged through
continuous professional
development programmes
Focus increased in areas other than Hep-C: Hep-B, Ortho-Rheuma,
Critical care
Market penetration into new disease areas and increased customer
base translating into higher market share
CARDIOLOGY & DIABETOLOGY
Strengthened the portfolio with anticoagulants, anti-diabetics, anti-
hypertensives, metabolic disorder therapies with novel products
Apigat achieved #1 position in prescriptions with extensive market
penetration and customer acquisition
Fortified anti-diabetic portfolio by introducing new-age gliptins like
sitagliptin
Capitalised on health & nutrition awareness phenomenon with
introduction of cutting-edge formulation of Vitamin D3- Nanonat D3
Expanding reach to wider base of doctors/patients/geographies
through NATCO Reach by adding 250+ sales executives
7View entire presentation